Jane Street’s Biocept, Inc. BIOC Stock Holding History

Jane Street’s Portfolio BIOC Stock Details BIOC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-847	Closed	-$8.64K	–	9977
2023 Q1	$8.64K	Buy	+847	New	+$12.3K	﹤0.01%	8755
2022 Q3	–	Sell	-469	Closed	-$13K	–	10786
2022 Q2	$13K	Buy	+469	New	+$21.4K	﹤0.01%	9263
2021 Q4	–	Sell	-373	Closed	-$45K	–	11056
2021 Q3	$45K	Buy	+373	New	+$43.5K	﹤0.01%	9576
2020 Q2	–	Sell	-59	Closed	-$5K	–	7717
2020 Q1	$5K	Buy	+59	New	+$6.04K	﹤0.01%	5214
2019 Q1	–	Sell	-44	Closed	-$11K	–	5839
2018 Q4	$11K	Buy	+44	New	+$22.1K	﹤0.01%	4818

Other funds holding BIOC

AFM

Anson Funds Management Dallas, Texas $2.29B AUM 370.1% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Jane Street's BIOC Position: Q2 2023 in Review

Jane Street sold out of Biocept, Inc. (BIOC) in Q2 2023, closing a stake of 847 shares — an estimated $8.64K sold.

Jane Street first reported a position in BIOC in Q4 2018 and held it in 5 quarters. The position peaked at $45K in Q3 2021. 11 funds tracked by Wall St. Rank hold BIOC as of Q2 2023.

Jane Street reported no remaining Biocept, Inc. position as of Q2 2023 after selling out during the quarter.
Jane Street sold 847 Biocept, Inc. shares in Q2 2023, an estimated $8.64K.
Jane Street first reported a position in Biocept, Inc. in Q4 2018 and held it in 5 quarters.
Jane Street's Biocept, Inc. position peaked at $45K in Q3 2021.
11 funds tracked by Wall St. Rank held Biocept, Inc. as of Q2 2023.

Based on Jane Street's 13F filing for Q2 2023, filed 14 Aug 2023.